# PHAI-105: Academic & Professional Writing
# Pharmacogenomics of CYP2D6 and Codeine Metabolism
# ====================================================
# Paper Outline — APA 7th Edition Format

---

# Title Page

**Title**: The Pharmacogenomics of CYP2D6 and Its Clinical Implications for Codeine Metabolism: A Review of Adverse Event Risk Across Metabolizer Phenotypes

**Author**: [Your Name]  
**Institution**: [Your Pharmacy School]  
**Course**: PHAI-105 — Academic & Professional Writing  
**Date**: [Submission Date]  

---

# Abstract (150–200 words)

> Summarise: background on CYP2D6 polymorphism, clinical significance of PM/UM phenotypes for codeine, key findings (FDA Black Box Warning, CPIC Level A evidence), and clinical implications for personalised prescribing.

**Keywords**: CYP2D6, codeine, pharmacogenomics, poor metabolizer, ultrarapid metabolizer, opioid safety, CPIC guidelines

---

# 1. Introduction

## 1.1 Background
- Global burden of pain management; codeine as a prodrug
- Introduction to pharmacogenomics and precision medicine
- Thesis statement: CYP2D6 genotype critically determines codeine efficacy and safety

## 1.2 Scope of Review
- Focus: CYP2D6 genetic variants → metabolizer phenotypes → clinical outcomes
- Populations: European, African, East Asian, South Asian
- Clinical settings: acute pain, post-surgical, pediatric, breastfeeding

---

# 2. CYP2D6 Enzyme Biology

## 2.1 Gene Structure and Location
- Chromosome 22q13.1
- Highly polymorphic: >150 known star alleles
- Gene duplication (*xN) and deletion (*5)

## 2.2 Enzyme Function
- Role in Phase I oxidative metabolism
- Substrate scope: ~25% of clinically used drugs
- Key substrates: codeine, tamoxifen, metoprolol, haloperidol, tramadol

## 2.3 Phenotype Classification (CPIC Consensus)
| Phenotype | Activity Score | Definition |
|-----------|---------------|------------|
| Poor Metabolizer (PM) | 0 | No functional alleles |
| Intermediate Metabolizer (IM) | 0.5–1.0 | Reduced enzyme activity |
| Normal Metabolizer (NM) | 1.0–2.0 | Full activity |
| Ultrarapid Metabolizer (UM) | >2.0 | Gene duplication / gain-of-function |

---

# 3. Codeine Pharmacokinetics and Pharmacogenomic Variability

## 3.1 Codeine as a Prodrug
- Bioactivation: codeine → morphine via CYP2D6 O-demethylation
- Active metabolite: morphine (10-fold more potent at μ-opioid receptors)
- Secondary pathway: codeine → norcodeine via CYP3A4 (inactive)

## 3.2 Pharmacokinetic Differences by Phenotype
- **PM**: Negligible morphine formation → therapeutic failure; norcodeine predominates
- **NM**: Predictable morphine levels; standard analgesic effect
- **UM**: Rapid, excess morphine generation → supratherapeutic concentrations

## 3.3 Population Allele Frequency Data
> *Include Table 2 with allele frequencies from PharmGKB / gnomAD across major ancestry groups*

---

# 4. Adverse Events and Clinical Case Evidence

## 4.1 PM Outcomes — Therapeutic Failure
- Systematic review data on NRS pain scores vs phenotype
- Economic burden of ineffective opioid prescribing

## 4.2 UM Outcomes — Toxicity and Mortality
- FDA 2013 safety communication on neonatal deaths
- Case: breastfeeding mother (UM) → neonatal opioid toxicity
- Post-surgical pediatric deaths (tonsillectomy + codeine)

## 4.3 Drug-Phenoconversion
- CYP2D6 inhibitors (fluoxetine, paroxetine) converting NM → functional PM
- Implications for polypharmacy patients

---

# 5. CPIC Guidelines and Clinical Decision Support

## 5.1 CPIC Level A Recommendation Summary
> *Reproduce recommendation table from CPIC 2021 guideline update*

## 5.2 Implementation Challenges
- Pre-emptive vs reactive genotyping
- Cost-effectiveness data
- EHR integration barriers

## 5.3 PharmGKB Evidence Framework
- Level 1A: Highly actionable — avoid codeine in PM/UM
- Clinical Annotation scoring methodology

---

# 6. Statistical Analysis (From PHAI-103 Data)

## 6.1 Hardy-Weinberg Equilibrium Analysis
> *Reference your PHAI-103 HWE output; report χ² and p-values across populations*

## 6.2 Concentration Variance by Phenotype
> *Report one-way ANOVA F-statistic, p-value, η² from concentration_regression.py*
> *Include Figure 1: Box plot of trough morphine concentrations by CYP2D6 phenotype*

---

# 7. Discussion

## 7.1 Clinical Implications
- Routine CYP2D6 genotyping before codeine prescribing
- Alternative analgesic choices for PM/UM patients

## 7.2 Limitations of Current Evidence
- Ethnicity gaps in clinical trial data
- Gene-environment interactions not fully characterised
- Limited prospective data in pediatric populations

## 7.3 Future Directions
- Polygenic risk scoring integrating CYP3A4, UGT2B7 with CYP2D6
- Pharmacist-led PGx consult services

---

# 8. Conclusion

> Concise synthesis: CYP2D6 genotype is clinically actionable, CPIC Level A evidence supports pre-emptive testing, pharmacists are ideally positioned to integrate PGx into medication management.

---

# References (APA 7th)

> Format: Author, A. A., & Author, B. B. (Year). Title of article. *Journal Name*, *Volume*(Issue), pages. https://doi.org/...

1. Crews, K. R., Monte, A. A., Huddart, R., et al. (2021). Clinical pharmacogenomics implementation consortium guideline for CYP2D6, OPRM1, and COMT genotypes and select opioid analgesics. *Clinical Pharmacology & Therapeutics*, *110*(4), 888–896. https://doi.org/10.1002/cpt.2149

2. U.S. Food and Drug Administration. (2013). *FDA drug safety communication: Safety review update of codeine use in children; new Boxed Warning and Contraindication on use after tonsillectomy and/or adenoidectomy*. FDA.

3. PharmGKB. (2024). *Codeine pathway, pharmacokinetics*. https://www.pharmgkb.org/pathway/PA146123006

4. Caudle, K. E., Dunnenberger, H. M., Freimuth, R. R., et al. (2017). Standardizing terms for clinical pharmacogenomic test results. *Genetics in Medicine*, *19*(2), 215–223.

5. Zanger, U. M., & Schwab, M. (2013). Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation. *Pharmacology & Therapeutics*, *138*(1), 103–141.

6. Ingelman-Sundberg, M. (2005). Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): Clinical consequences, evolutionary aspects and functional diversity. *The Pharmacogenomics Journal*, *5*, 6–13.

7. Gaedigk, A., Simon, S. D., Pearce, R. E., et al. (2008). The CYP2D6 activity score: Translating genotype information into a qualitative measure of phenotype. *Clinical Pharmacology & Therapeutics*, *83*(2), 234–242.

---

*Word count target: ~1,500–2,000 words for body sections (excluding abstract, tables, references)*  
*Zotero collection: PHAI-105_CYP2D6_Codeine*
